Dishaman Pharmaceuticals & Chemicals Ltd has posted a consolidated net profit of Rs 1.74 crore for the quarter ended December 31, 2010, down 94.65 per cent from the same period last fiscal when the company had posted a net profit of Rs 32.53 crore.
Dishman said in a statement that the performance of the company is adversely impacted owing to a lower than expected performance of the Swiss subsidiary Carbogen Amcis AG and adverse currency movement, as well as rising material costs.
The consolidated turnover of the company increased by 4.26 per cent to Rs 231.76 crores as against Rs 222.30 crores in the corresponding period previous year. The raw material costs for the quarter nearly doubled from Rs 41.73 crore to Rs 83.46 crore. While the contract research and manufacturing segment (CRAMS) posted a dip in revenues to Rs 152.17 crore from Rs 160.72 crore, the marketable molecules segment recorded a rise in revenues to Rs 73.58 crore from Rs 61.57 crore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
